EGFR and head and neck squamous cell carcinoma: In addition to cytotoxic chemotherapies, cetuximab, an anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody, was the first targeted agent to gain FDA approval in treating locally advanced HNSCC [48,49].